CRGX (Cargo Therapeutics) ROE % Adjusted to Book Value : -25.96% (As of Dec. 2024)

View and export this data going back to 2023. Start your Free Trial

What is Cargo Therapeutics ROE % Adjusted to Book Value?

Cargo Therapeutics's ROE % for the quarter that ended in Dec. 2024 was -47.76%. Cargo Therapeutics's PB Ratio for the quarter that ended in Dec. 2024 was 1.84. Cargo Therapeutics's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2024 was -25.96%.

Cargo Therapeutics ROE % Adjusted to Book Value Historical Data

The historical data trend for Cargo Therapeutics's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cargo Therapeutics ROE % Adjusted to Book Value Chart

Cargo Therapeutics Annual Data

Trend

Dec21

Dec22

Dec23

Dec24

ROE % Adjusted to Book Value

-22.57

-23.78

Cargo Therapeutics Quarterly Data
	Dec21	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
ROE % Adjusted to Book Value	Get a 7-Day Free Trial							-36.89	-15.66	-25.34	-18.90	-25.96

Competitive Comparison of Cargo Therapeutics's ROE % Adjusted to Book Value

For the Biotechnology subindustry, Cargo Therapeutics's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cargo Therapeutics's ROE % Adjusted to Book Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cargo Therapeutics's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Cargo Therapeutics's ROE % Adjusted to Book Value falls into.

Cargo Therapeutics ROE % Adjusted to Book Value Calculation

Cargo Therapeutics's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2024 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	-43.76%	/	1.84
	=	-23.78%

Cargo Therapeutics's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2024 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	-47.76%	/	1.84
	=	-25.96%

Cargo Therapeutics ROE % Adjusted to Book Value Related Terms

Thank you for viewing the detailed overview of Cargo Therapeutics's ROE % Adjusted to Book Value provided by GuruFocus.com. Please click on the following links to see related term pages.

Cargo Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cargo Therapeutics Inc (NAS:CRGX) » Definitions » ROE % Adjusted to Book Value

Comparable Companies

Traded in Other Exchanges

N/A

Address

835 Industrial Road, Suite 400, San Carlos, CA, USA, 94070

Website

https://www.cargo-tx.com

Cargo Therapeutics Inc is a clinical-stage biotechnology company positioned to advance next generation, potentially curative cell therapies for cancer patients. It programs, platforms, and manufacturing are designed to directly address the limitations of approved chimeric antigen receptor (CAR) T-cell therapies. Its product includes CRG-023, an investigational tri-specific CAR T designed to address several known causes of relapse associated with existing CAR T-cell therapies such as loss of tumor antigen expression, loss of co-stimulation (e.g., via CD58/CD2 signaling) and T cell exhaustion. CRG-023 is designed to target the B-cell lineage antigens (CD19, CD20, CD22) via tri-cistronic expression of three distinct CARs from a single lentiviral vector.